DoD Awards $876,000 Grant to Advance Lung Cancer Biomarker Research at Cedars-Sinai

The U.S. Department of Defense has awarded Cedars-Sinai Medical Center $876,000 to support critical biomarker research for Kairos Pharma's experimental lung cancer treatment ENV105. The grant will fund research in Dr. Neil Bhowmick's laboratory, targeting patients with EGFR-driven non-small cell lung cancer who are developing resistance to osimertinib, a standard treatment.

The study aims to identify biomarkers that could help clinicians determine which patients might benefit from early intervention with ENV105, a novel therapeutic approach. By focusing on CD105, a protein key to understanding drug resistance, researchers hope to develop more precise and effective cancer treatments that can overcome current therapeutic limitations.

ENV105 represents a potential breakthrough in oncology, targeting the CD105 protein that contributes to treatment resistance and disease relapse. The research could provide crucial insights into managing lung cancer, a disease with significant unmet medical needs and challenging treatment trajectories.

This Department of Defense funding underscores the strategic importance of innovative cancer research and highlights Kairos Pharma's commitment to developing targeted therapies that could potentially improve long-term patient outcomes. The grant enables further exploration of mechanisms that contribute to cancer treatment resistance, potentially opening new pathways for more effective personalized medicine.